Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 38660 | 7.74 |
09:34 ET | 7125 | 7.59 |
09:36 ET | 3881 | 7.65 |
09:38 ET | 12730 | 7.58 |
09:39 ET | 6964 | 7.5513 |
09:41 ET | 17380 | 7.65 |
09:43 ET | 13835 | 7.7 |
09:45 ET | 8016 | 7.62 |
09:48 ET | 5015 | 7.61 |
09:50 ET | 2225 | 7.575 |
09:52 ET | 25849 | 7.58 |
09:54 ET | 12103 | 7.6295 |
09:56 ET | 28647 | 7.67 |
09:57 ET | 10499 | 7.74 |
09:59 ET | 14855 | 7.75 |
10:01 ET | 15930 | 7.74 |
10:03 ET | 18591 | 7.8 |
10:06 ET | 41017 | 7.905 |
10:08 ET | 17898 | 7.83 |
10:10 ET | 16548 | 7.7701 |
10:12 ET | 18854 | 7.815 |
10:14 ET | 12177 | 7.795 |
10:15 ET | 16198 | 7.83 |
10:17 ET | 15500 | 7.84 |
10:19 ET | 17053 | 7.835 |
10:21 ET | 11277 | 7.85 |
10:24 ET | 15303 | 7.83 |
10:26 ET | 18804 | 7.825 |
10:28 ET | 10872 | 7.885 |
10:30 ET | 5319 | 7.88 |
10:32 ET | 35309 | 7.88 |
10:33 ET | 19920 | 7.88 |
10:35 ET | 2567 | 7.8911 |
10:37 ET | 16924 | 7.91 |
10:39 ET | 9778 | 7.905 |
10:42 ET | 10195 | 7.88 |
10:44 ET | 8323 | 7.905 |
10:46 ET | 23353 | 7.9302 |
10:48 ET | 10537 | 7.95 |
10:50 ET | 49145 | 8.015 |
10:51 ET | 37805 | 8 |
10:53 ET | 7657 | 8 |
10:55 ET | 18650 | 7.9502 |
10:57 ET | 4994 | 7.99 |
11:00 ET | 3309 | 8.01 |
11:02 ET | 30564 | 7.95 |
11:04 ET | 12800 | 7.94 |
11:06 ET | 8770 | 7.93 |
11:08 ET | 10146 | 7.99 |
11:09 ET | 4357 | 7.96 |
11:11 ET | 8842 | 7.91 |
11:13 ET | 81699 | 7.86 |
11:15 ET | 9902 | 7.91 |
11:18 ET | 4645 | 7.89 |
11:20 ET | 4800 | 7.8999 |
11:22 ET | 7501 | 7.905 |
11:24 ET | 1746 | 7.895 |
11:26 ET | 9826 | 7.92 |
11:27 ET | 5031 | 7.89 |
11:29 ET | 4737 | 7.885 |
11:31 ET | 9600 | 7.904 |
11:33 ET | 12576 | 7.8901 |
11:36 ET | 9601 | 7.92 |
11:38 ET | 18939 | 7.975 |
11:40 ET | 13141 | 8.0102 |
11:42 ET | 11352 | 7.98 |
11:44 ET | 2647 | 7.995 |
11:45 ET | 10087 | 7.9701 |
11:47 ET | 5182 | 7.98 |
11:49 ET | 11491 | 7.97 |
11:51 ET | 5580 | 7.96 |
11:54 ET | 4484 | 7.995 |
11:56 ET | 2886 | 8.01 |
11:58 ET | 9906 | 8.03 |
12:00 ET | 3607 | 8.025 |
12:02 ET | 8021 | 8.06 |
12:03 ET | 7720 | 8.035 |
12:05 ET | 8634 | 8.04 |
12:07 ET | 4043 | 8.01 |
12:09 ET | 3311 | 8.01 |
12:12 ET | 55242 | 7.97 |
12:14 ET | 14273 | 7.9187 |
12:16 ET | 6859 | 7.91 |
12:18 ET | 3160 | 7.9 |
12:20 ET | 9895 | 7.93 |
12:21 ET | 9029 | 7.94 |
12:23 ET | 1937 | 7.935 |
12:25 ET | 5910 | 7.9505 |
12:27 ET | 9590 | 7.93 |
12:30 ET | 7828 | 7.965 |
12:32 ET | 18611 | 7.94 |
12:34 ET | 2952 | 7.9307 |
12:36 ET | 14651 | 7.88 |
12:38 ET | 15702 | 7.88 |
12:39 ET | 14845 | 7.92 |
12:41 ET | 5178 | 7.9198 |
12:43 ET | 4318 | 7.91 |
12:45 ET | 300 | 7.9 |
12:48 ET | 6209 | 7.905 |
12:50 ET | 3644 | 7.915 |
12:52 ET | 1500 | 7.915 |
12:54 ET | 2971 | 7.9 |
12:56 ET | 1612 | 7.9 |
12:57 ET | 8110 | 7.89 |
12:59 ET | 2643 | 7.915 |
01:01 ET | 4355 | 7.905 |
01:03 ET | 3796 | 7.905 |
01:06 ET | 8447 | 7.935 |
01:08 ET | 5493 | 7.88 |
01:10 ET | 10528 | 7.815 |
01:12 ET | 11187 | 7.83 |
01:14 ET | 2572 | 7.825 |
01:15 ET | 3238 | 7.835 |
01:17 ET | 700 | 7.835 |
01:19 ET | 1400 | 7.845 |
01:21 ET | 3401 | 7.845 |
01:24 ET | 600 | 7.84 |
01:26 ET | 8668 | 7.855 |
01:28 ET | 2848 | 7.85 |
01:30 ET | 5165 | 7.84 |
01:32 ET | 1592 | 7.845 |
01:33 ET | 13407 | 7.84 |
01:35 ET | 3239 | 7.865 |
01:37 ET | 1266 | 7.865 |
01:39 ET | 17673 | 7.87 |
01:42 ET | 1909 | 7.84 |
01:44 ET | 14753 | 7.78 |
01:46 ET | 16171 | 7.77 |
01:48 ET | 3883 | 7.79 |
01:50 ET | 28756 | 7.83 |
01:51 ET | 13005 | 7.79 |
01:53 ET | 10200 | 7.79 |
01:55 ET | 9032 | 7.82 |
01:57 ET | 1809 | 7.825 |
02:00 ET | 2052 | 7.795 |
02:02 ET | 3950 | 7.805 |
02:04 ET | 1659 | 7.81 |
02:06 ET | 2816 | 7.785 |
02:08 ET | 5231 | 7.765 |
02:09 ET | 3598 | 7.77 |
02:11 ET | 4074 | 7.76 |
02:13 ET | 2883 | 7.7361 |
02:15 ET | 7383 | 7.765 |
02:18 ET | 2582 | 7.765 |
02:20 ET | 3868 | 7.775 |
02:22 ET | 2243 | 7.76 |
02:24 ET | 6122 | 7.75 |
02:26 ET | 1700 | 7.745 |
02:27 ET | 8316 | 7.72 |
02:29 ET | 1700 | 7.7 |
02:31 ET | 7133 | 7.705 |
02:33 ET | 3952 | 7.73 |
02:36 ET | 3639 | 7.705 |
02:38 ET | 1264 | 7.71 |
02:40 ET | 5727 | 7.72 |
02:42 ET | 2396 | 7.71 |
02:44 ET | 4501 | 7.725 |
02:45 ET | 11494 | 7.745 |
02:47 ET | 4091 | 7.75 |
02:49 ET | 2178 | 7.765 |
02:51 ET | 1286 | 7.765 |
02:54 ET | 12848 | 7.775 |
02:56 ET | 8182 | 7.795 |
02:58 ET | 1608 | 7.775 |
03:00 ET | 6242 | 7.78 |
03:02 ET | 2779 | 7.795 |
03:03 ET | 6468 | 7.785 |
03:05 ET | 8320 | 7.805 |
03:07 ET | 3641 | 7.82 |
03:09 ET | 2252 | 7.82 |
03:12 ET | 6912 | 7.83 |
03:14 ET | 6943 | 7.85 |
03:16 ET | 17135 | 7.85 |
03:18 ET | 9609 | 7.835 |
03:20 ET | 14415 | 7.865 |
03:21 ET | 16640 | 7.875 |
03:23 ET | 20009 | 7.84 |
03:25 ET | 6963 | 7.845 |
03:27 ET | 6738 | 7.845 |
03:30 ET | 12404 | 7.875 |
03:32 ET | 37469 | 7.89 |
03:34 ET | 11216 | 7.885 |
03:36 ET | 35165 | 7.825 |
03:38 ET | 20898 | 7.785 |
03:39 ET | 20690 | 7.845 |
03:41 ET | 27442 | 7.85 |
03:43 ET | 13746 | 7.855 |
03:45 ET | 5701 | 7.87 |
03:48 ET | 10212 | 7.86 |
03:50 ET | 7567 | 7.845 |
03:52 ET | 17910 | 7.845 |
03:54 ET | 43013 | 7.865 |
03:56 ET | 32392 | 7.935 |
03:57 ET | 64182 | 7.95 |
03:59 ET | 153852 | 7.98 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.6B | -48.2x | --- |
BridgeBio Pharma Inc | 5.2B | -8.6x | --- |
Madrigal Pharmaceuticals Inc | 5.0B | -11.0x | --- |
Cytokinetics Inc | 6.3B | -10.0x | --- |
Viking Therapeutics Inc | 6.5B | -60.6x | --- |
Nuvalent Inc | 4.7B | -33.2x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.4B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.95 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -48.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.